Zylox-Tonbridge, a Hong Kong-listed medical technology company focused on neuro-and peripheral vascular interventional products and solutions, announced that it has entered into a definitive agreement to acquire a Germany-based medical technology company, Optimed Medizinische Instrumente GmbH, specialising in research and development, production and distribution of medical devices for minimally invasive therapy worldwide, in multiple steps. Under the terms of the agreement, Zylox-Tonbridge has the option to acquire the entire equity interest in Optimed from its existing shareholders.
Optimed is a leading medical technology company specialising in minimally invasive vascular and endourology devices. Over nearly three decades, Optimed has developed an extensive sales and service network spanning more than 70 countries worldwide and has developed long-standing relationships with physicians and key opinion leaders in Europe and other key markets. Optimed has one of the most comprehensive product portfolios in the peripheral venous stenting market, including specialised devices for the iliofemoral veins, the iliac bifurcation and the vena cava. Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence from STEVECO, the first prospective, randomised, multicenter trial in this chronic deep venous obstruction setting, which demonstrated significant improvements in quality of life and clinical severity compared with conservative treatment.
The acquisition of Optimed accelerates Zylox-Tonbridge's global expansion by establishing a unified platform spanning research and development, manufacturing, and commercialisation. By integrating both companies' sales networks and leveraging Optimed's long-standing relationships with European clinical experts, Zylox-Tonbridge will be positioned to bring products to market more efficiently and expand its global reach. Furthermore, this partnership is also expected to generate significant operational synergies, supported by an expanded manufacturing base in Germany to ensure a high-quality, reliable supply of innovative medical solutions for European and global markets. Following the closing of the transaction, Zylox-Tonbridge will integrate its sales, marketing, and customer service teams with those of Optimed to create one unified global commercial organisation. Rüdiger Hausherr will continue to serve as Chief Executive Officer of Optimed and will report to Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge.
